- Current advances in immunotherapy in early-stage gastroesophageal junction (GEJ) cancer
- Selection of therapy for previously untreated gastric/GEJ cancers
- Incorporating new therapeutic strategies and agents available for previously treated patients in the second-line and beyond
- Identification and management of common and serious adverse events associated with immunotherapy and targeted therapy
- Review of ongoing clinical trials
- Audience question & answer session
Date / Time
Jaffer Ajani, MD
Professor of Medicine
Department of GI Medical Oncology
The University of Texas MD Anderson Cancer Center
David H. Ilson, MD, PhD
Professor of Medicine
Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center
New York, New York
Samuel Klempner, MD
Division of Hematology-Oncology
Department of Medicine
Mass General Cancer Center
Harvard Medical School
Nataliya Uboha, MD, PhD
University of Wisconsin, Carbone Cancer Center
Zev A. Wainberg, MD
Assistant Professor, Hematology/Oncology
University of California, Los Angeles
Los Angeles, California
The goal of this activity is to improve the knowledge, confidence, competence of community care teams in integrating the available clinical data, guidelines, and expert recommendations into the care of their patients with gastroesophageal cancers.
This program is intended for nurses, pharmacists, oncologists and other healthcare professionals involved in the treatment of patients with gastroesophageal cancers.
Upon completion of this activity, participants should be able to:
- Identify appropriate patients with completely resected esophageal or GEJ cancer who are candidates for adjuvant immunotherapy
- Plan frontline immune checkpoint inhibitor–based therapy for appropriate patients based on recent clinical data and current indications in esophageal squamous cell carcinoma
- Develop optimal sequencing of agents for patients with HER2-positive gastric/GEJ cancer
- Incorporate histology-agnostic targeted therapy into treatment plans using newly approved indications
- Manage treatment-related symptoms for patient with gastric, GEJ, or esophageal squamous cell carcinoma
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-027-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.